Redeye returns with an update following AlzeCure's Q2 earnings release, which aligned with our expectations. AlzeCure recently strengthened its cash position and is moving closer to clinical trials, including a phase IIa study with NeuroRestore ACD856 in Alzheimer’s. With the successful capital raise incorporated in our model, we land in a slightly increased fair value range. This update also provides a recap of the NeuroRestore program.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/